Cartherics Secures Chinese Patent for Enhanced NK Cell Therapy Targeting Solid Tumors
核心洞察
Cartherics (搜索) has been granted a Chinese patent for a method to enhance immune cell function by knocking out the adenosine A2A receptor (搜索) in induced pluripotent stem cells.
The patent covers technology that prevents immune suppression in solid tumor environments where adenosine concentrations are high, allowing NK cells to maintain their cancer-fighting capabilities.
This intellectual property strengthens Cartherics (搜索)' pipeline focused on women's health conditions including ovarian cancer (搜索), triple-negative breast cancer (搜索), and endometriosis (搜索).
Melbourne-based biotechnology company Cartherics (搜索) has been granted a Chinese patent for "Method for Providing Immune Cells with Enhanced Function," marking a significant advancement in the company's mission to develop off-the-shelf immune cell therapies for high-impact women's diseases. The patent covers induced pluripotent stem cells (iPSCs (搜索)) engineered with a specific gene knockout of the adenosine A2A receptor (搜索) (A2AR (搜索)).
Overcoming Immune Suppression in Solid Tumors
The adenosine A2A receptor (搜索) plays a critical role in inhibiting immune cell function within the tumor microenvironment of solid tumors (搜索). Adenosine, which is found in high levels in solid tumors, suppresses the activity of immune cells like natural killer (NK) cells. By removing the A2A receptor from Cartherics (搜索)' NK cells, these cells are expected to remain active in the tumor microenvironment, maintaining their cancer-fighting capabilities even where adenosine concentrations are high.
"Cartherics (搜索)' approach to destroying solid tumors (搜索) involves editing critical genes in our cell products to enable the immune system to function as it was designed — to control cancer growth," said Professor Alan Trounson AO, CEO of Cartherics. "Blocking the A2AR (搜索) gene is likely to be a significant addition to our strategic arsenal against cancer."
Strategic IP Portfolio Enhancement
This patent secures a proprietary position for multiple development candidates in Cartherics (搜索)' pipeline and strengthens the company's intellectual property position. The patent provides valuable commercial weight given China's large and growing biopharmaceutical market and its strong system of patent protection.
The development reinforces Cartherics (搜索)' strategy of deploying advanced gene-editing technologies to overcome the barriers that have long limited the effectiveness of cell therapies in solid tumors (搜索).
Focus on Women's Health
Cartherics (搜索) is advancing its mission to transform women's health through innovative, off-the-shelf immunotherapies. The company's pipeline targets high-need indications including ovarian cancer (搜索), triple-negative breast cancer (搜索), and endometriosis (搜索). The company's off-the-shelf immunotherapy approach, based on stem-cell-derived NK and T cells, aims to deliver scalable and accessible treatments without the logistical challenges associated with patient-specific cell therapies.
The combination of strong intellectual property, a robust clinical development pathway, and the scale of its target markets positions Cartherics (搜索) to play a leading role in the next generation of immunotherapies targeting markets with significant unmet clinical need and commercial potential.